A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Michael Siluk | UCG | Universal Images Group | Getty Images Losing weight with GLP-1 drugs is only half the …
Biotechnology
Medicare will start covering obesity drugs for the first time. Here’s what patients should know
Millions of older Americans in Medicare are about to receive a benefit that has never existed before: coverage of obesity …
As the largest World Cup ever kicks off, health officials are focused on more than Ebola
As athletes and millions of fans gear up for the FIFA World Cup starting next week, global health officials are …
Hantavirus outbreak isn’t another Covid pandemic – but experts say it’s testing U.S. readiness
A cruise ship outbreak of hantavirus has rattled the public and reignited fears of another global health scare as passengers …
Novo Nordisk’s explosive Wegovy pill launch draws a new wave of patients into GLP-1 weight loss treatment
After years of trying to lose weight “the right way,” Jane Zuckerman realized that “putting in the work just wasn’t …
Novo Nordisk faces a defining year in the obesity drug market. It’s off to a dramatic start
Mike Doustdar, CEO of Novo Nordisk, speaks in the Oval Office during an event about weight loss drugs at the …
What obesity drugmakers see next in the market: More pills, easier access and drug combinations
A pharmacist displays a box of Wegovy pills at a pharmacy in Provo, Utah, Jan. 15, 2026. George Frey | …
Drug pricing, patent losses and deals: Here’s what pharma execs see ahead in the industry
President Donald Trump arrives for an announcement in the Roosevelt Room of the White House in Washington, Dec. 19, 2025. …
2026 is the year of obesity pills. Here’s how they could reshape the GLP-1 market
The booming GLP-1 space was built on weekly injections. In 2026, new obesity pills will push the market into its …
CNBC’s Becky Quick details daughter’s rare disease journey
I’ve spent the last 25 years in front of the camera here at CNBC, and people have gotten to know …